Structure–Activity Relationship Study of Rakicidins: Overcoming Chronic Myeloid Leukemia Resistance to Imatinib with 4-Methylester-Rakicidin A
作者:Feng Sang、Yahui Ding、Jinghan Wang、Bingxia Sun、Jianlei Sun、Yan Geng、Zhang Zhang、Ke Ding、Ling-Ling Wu、Jian-Wei Liu、Cuigai Bai、Guang Yang、Quan Zhang、Lu-Yuan Li、Yue Chen
DOI:10.1021/acs.jmedchem.5b01841
日期:2016.2.11
greater potency against the imatinib-resistant cell line K562/G+ and approximately 100-fold enhanced potency compared with that of imatinib. Furthermore, compound 1a demonstrated a significantly lower resistance index against Ba/F3 cells expressing BCR-ABLT315I than bosutinib, dasatinib, nilotinib, and ponatinib, while 1a exhibited less effect on normal hematopoietic cells. Preliminary results indicated
天然产物rakicidin A在耐TKI的慢性粒细胞性白血病(CML)细胞中诱导细胞死亡。因此,通过高效的组合策略合成了14种rakicidin A类似物,并针对CML细胞系进行了评估。发现共轭二烯部分对于rakicidin A的抗CML活性至关重要,并且导致了C-2,C-3,C-14,C-15和C-16构型的变化在较低水平的抗CML活性。最有前途的化合物是4-甲酯rakicidin A(1a)。与rakicidin A相比,1a对伊马替尼耐药细胞系K562 / G +的效力提高了2.8倍,与伊马替尼相比,其效力提高了约100倍。此外,化合物1a证明对表达BCR-ABL T315I的Ba / F3细胞的耐药指数明显低于波舒替尼,达沙替尼,尼洛替尼和ponatinib,而1a对正常造血细胞的影响较小。初步结果表明1a下调了caspase-3和PARP,这有助于其对K562细胞的抑制活性。